In this article
TB-500 is a synthetic peptide based on thymosin beta-4, a protein the body makes naturally and that is involved in cell movement, tissue remodeling and blood-vessel growth. Reported TB-500 benefits relate mostly to muscle, tendon and cardiac repair, but the evidence is largely preclinical. It is a research compound and not approved for human use.
- TB-500 is modeled on thymosin beta-4, found in nearly all cells and especially abundant in platelets.
- Its main proposed role is helping cells migrate to damaged tissue, alongside effects on inflammation and angiogenesis.
- Human clinical evidence is limited; many claims are anecdotal.
- Signal IQ lists research protocols of 500 mcg to 1 mg, given subcutaneously on a set weekly schedule.
- It is often compared with BPC-157, but the two are studied through different mechanisms.
What is TB-500?
Thymosin beta-4 is a naturally occurring peptide of 43 amino acids. It is present in virtually all human and animal cells and is concentrated in blood platelets. Natural thymosin beta-4 takes part in repair, cell movement and wound response.
TB-500 is the name used for the synthetic version studied in the lab. Descriptions vary on whether it is the full sequence or a fragment, which is one reason batch identity and testing matter. See how to read a peptide COA for what to check.
How TB-500 is thought to work
Cell migration
The central idea is that thymosin beta-4 helps cells travel to injury sites. It does this in part by affecting actin, a protein cells use to move. Researchers have also looked at effects on stem cell differentiation and general tissue regeneration.
Inflammation
Studies describe lower levels of pro-inflammatory cytokines and higher anti-inflammatory markers. The overall picture is of a more balanced immune response around damaged tissue.
Angiogenesis
Like BPC-157, TB-500 is linked to the formation of new blood vessels, which may improve blood flow and nutrient delivery to injured areas.
Areas where research reports effects
| Area | What is reported | Strength of evidence |
|---|---|---|
| Muscle and tendon | Support for fiber regeneration and tendon repair; less scar tissue | Mostly preclinical |
| Heart tissue | Possible support for repair after injury and reduced inflammation | Early research |
| Skin and hair | Faster skin healing, less scarring, hair follicle stimulation | Limited |
| Mobility | Anecdotal reports of looser joints and less stiffness | Anecdotal |
TB-500 compared with BPC-157
The two peptides are often discussed together because both are linked to repair, but they differ in how they are described and used.
| Factor | TB-500 | BPC-157 |
|---|---|---|
| Typical focus | Systemic effects | Often discussed for localized injuries |
| Dosing frequency | A few times per week | Once daily in most protocols |
| Half-life | Described as longer | Described as shorter |
| Main proposed mechanism | Cell migration, actin | Angiogenesis, growth factors, nitric oxide |
For more detail, read the BPC-157 guide and the BPC-157 and TB-500 stack overview. There is no strong human evidence that combining them is better than either alone.
Dosing ranges reported in research protocols
The TB-500 compound page on Signal IQ lists the ranges below. They describe published research protocols, not a personal recommendation.
| Item | Reported range |
|---|---|
| Per-injection amount | 500 mcg to 1 mg (5 to 10 units on a 5 mg/mL mix) |
| Schedule | 5 days on and 2 days off, or 3 injections per week |
| Route | Subcutaneous |
| Common vial sizes | 10 to 20 mg |
A 10 mg vial mixed with 1 mL of bacteriostatic water, or a 20 mg vial with 2 mL, gives the same concentration. For the mechanics, see how to reconstitute peptides, bacteriostatic water vs sterile water and insulin syringe units.
TB-500 is generally described as a systemic compound, so injection does not need to be near a specific site. Duration is not firmly defined; effects are usually evaluated over weeks of consistent use. For scheduling concepts, see peptide cycling.
Safety considerations
Side effects are described as uncommon and may include injection-site reactions, temporary fatigue and, rarely, a brief head rush. Pregnancy is a commonly cited reason to avoid it. Because angiogenesis and cell growth are involved, caution is raised for anyone with active cancer. Long-term human safety data are lacking.
To explore other options by goal, use peptides by goal or ask Pulse.
Frequently asked questions
How long does TB-500 take to work?
No timeline has been established in humans. Anecdotal accounts mention a few weeks, but they are not controlled data.
Where is TB-500 injected?
Research protocols describe subcutaneous injection. Because it is considered systemic, it is not described as needing to be near the injury. See peptide injection sites.
Can TB-500 help old injuries?
Some people report it for long-standing problems, but this is anecdotal. Preclinical work focused mainly on fresh injury models.
Is TB-500 the same as thymosin beta-4?
Not exactly. TB-500 is a synthetic version based on thymosin beta-4, and descriptions differ on whether it is the full sequence or a fragment. Testing documentation helps confirm what a batch contains.
Is TB-500 approved by the FDA?
No. It is a research compound and not approved for human use.
Can TB-500 be mixed with BPC-157 in one syringe?
That raises stability and handling questions. See can you mix peptides in the same syringe.
Go deeper on Signal IQ
Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.
Ask PulseEducational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.



